Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 22

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 22
---
2025 Proxy Statement
| Information Regarding the Board of Directors and Corporate Governance |

Report of the Audit Committee of the Board of Directors*

The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2024, with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (the “PCAOB”). The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm’s independence. Based on the foregoing, the Audit Committee has recommended to the board of directors that the audited financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

#### •

#### G. Bradley Cole

#### (Chair)
#### •

#### Kimberlee S. Caple
#### •

#### Rodney Cotton
#### •

#### Tiffany P. Olson
* The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

#### Compensation Committee
Our Compensation Committee consists of Miles D. Harrison, G. Bradley Cole , Rodney Cotton , and Ellen Goldberg . Mr. Harrison serves as the Chair of our Compensation Committee. Effective as of the close of the Annual Meeting, Ms. Goldberg will replace Mr. Harrison as Chair of the Compensation Committee. Our board of directors has determined that each of the members of our Compensation Committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act, and satisfies the applicable Nasdaq independence requirements. All members of the Company’s Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing rules). The Compensation Committee met three times during the last fiscal year. The board of directors has adopted a written Compensation Committee Charter that is available to stockholders on the Company’s website at www.CastleBiosciences.com on the “Invest